GlycoEra
Private Company
Total funding raised: $40M
Overview
GlycoEra is a private, pre-clinical-stage biotech developing extracellular protein degraders for autoimmune diseases. Its proprietary platform enables deep (>95%), rapid (under 30 minutes), and selective degradation of pathogenic proteins like autoantibodies without causing broad immunosuppression. The company is advancing its lead program, GE8820, targeting pathogenic IgG4 autoantibodies, and has raised significant capital ($130M) to validate its platform and pipeline.
Technology Platform
Proprietary protein engineering platform for developing biologics that selectively and rapidly degrade specific circulating extracellular proteins (e.g., autoantibodies) with high specificity and without broad immunosuppression.
Funding History
2Opportunities
Risk Factors
Competitive Landscape
GlycoEra competes with developers of monoclonal antibodies, Fc receptor modulators, and other novel immunology therapies from large pharma and biotech. Its direct competition comes from other companies exploring extracellular protein degradation (e.g., using lysosomal targeting), but its claimed speed and depth of degradation aim to differentiate it within this emerging modality.